10.01.2024
Poised for Growth
With a pipeline of promising therapeutics, Merakris is well positioned to be at the forefront of the cellular regenerative market which is expected to reach $40 billion by 2027, driven by rising healthcare costs and increasing demand for innovative treatment options.
Our investors and partners make it possible to pioneer new regenerative treatment options and provide access to our patients and providers across the globe.
Investor Contact
Contact us today to learn more about our investment opportunities and become a part of our journey.
"*" indicates required fields